Goulding A

No ORCID on file · 3 papers in corpus
other 1993
Norethindrone acetate only partially protects the skeleton of rats treated with the LHRH agonist buserelin from oestrogen-deficiency osteopaenia
The Journal of endocrinology ·doi:10.1677/joe.0.1370027

In women with endometriosis there is concern that therapeutic use of LH-releasing hormone (LHRH) analogues, to lower ovarian oestrogen production and control endometrial hyperplasia, leads to unwanted oestrogen-deficiency bone loss. We have…

article 1992
Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin
Bone and mineral ·doi:10.1016/0169-6009(92)90854-7

In young women chronic use of luteinizing hormone releasing hormone (LHRH) agonists such as buserelin to treat endometriosis leads to estrogen-deficiency bone loss. Tamoxifen citrate is an estrogen agonist/antagonist which protects the skel…

article 1991
Preventive effects of clomiphene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research ·doi:10.1002/jbmr.5650061106

The estrogen agonist and antagonist clomiphene citrate has been shown to prevent bone loss induced by ovariectomy in the rat. In young women estrogen-deficiency bone loss is a clinical problem associated with the use of luteinizing hormone …